Breaking News Instant updates and real-time market news.

VRX

Valeant

$16.45

0.22 (1.36%)

14:54
04/12/18
04/12
14:54
04/12/18
14:54

Valeant says Arbitral Tribunal issues favorable decision on Uceris

Valeant Pharmaceuticals announced that the Arbitral Tribunal issued a decision, rendered on April 9, relating to the arbitration between Santarus and Valeant and Cosmo Technologies, the licensor of certain intellectual property rights in, and supplier of, Valeant's Uceris extended release tablets. The arbitration focused on Cosmo's allegations that Valeant had breached the License Agreement and Manufacturing and Supply Agreement between the parties and Cosmo's claim that it had validly terminated the Agreements. Valeant denied each of Cosmo's allegations and claims. On April 12, the Tribunal issued a ruling rejecting Cosmo's claims in their entirety; accordingly, both the License Agreement and the Manufacturing and Supply Agreement remain in effect. Additionally, the Arbitral Tribunal ordered Cosmo to pay the entirety of Valeant's legal costs, or $3,063,960. Valeant said it "will continue to vigorously defend itself against these and other claims and allegations."

  • 08

    May

  • 13

    May

  • 18

    Jun

  • 27

    Aug

VRX Valeant
$16.45

0.22 (1.36%)

03/21/18
DBAB
03/21/18
NO CHANGE
Target $20
DBAB
Buy
Deutsche Bank continues to like risk/reward for Valeant shares
Valeant Pharmaceuticals could get more credit for its dermatology pipeline over time as it discloses more details on assets, secures approvals, and executes on launches, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He notes that one key difference between Valeant's longer-term outlook and his model is sales potential for the dermatology business. Management believes it can double sales from 2018-2022 to greater than $1B while Gilbert's estimates are much lower at $600M, likely due to lower pipeline contribution. He believes success in dermatology would represent "significant upside" to his current price target of $20. The analyst continues to like the risk/reward for the stock and maintains a Buy rating on Valeant.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Valeant upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Valeant to Neutral and raised its price target to $15 from $10. Koffler sees a lack of near-term sell catalysts and views 2018 guidance as achievable.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Mizuho upgrades Valeant to Neutral on lack of negative catalysts
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals to Neutral from Underperform and raised her price target for the shares to $15 from $10. The drugmaker closed yesterday at $15.79. The analyst, while remaining concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." Further, she views the company's 2018 guidance as achievable.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

, DIS

Disney

$101.21

-1 (-0.98%)

05:49
04/19/18
04/19
05:49
04/19/18
05:49
Hot Stocks
21st Century Fox rejected rival bid of $34.41 per share for assets »

Disney (DIS) disclosed…

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

DIS

Disney

$101.21

-1 (-0.98%)

CMCSA

Comcast

$33.28

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 09

    May

NTRS

Northern Trust

$106.38

-0.04 (-0.04%)

05:47
04/19/18
04/19
05:47
04/19/18
05:47
Hot Stocks
Northern Trust enters partnership with The Northern Pool »

The Northern Pool has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$81.72

-0.09 (-0.11%)

, AMGN

Amgen

$175.14

0.19 (0.11%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Hot Stocks
Novartis appoints John Tsai as Chief Medical Officer, Head of GDD »

Novartis (NVS) announced…

NVS

Novartis

$81.72

-0.09 (-0.11%)

AMGN

Amgen

$175.14

0.19 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 21

    May

  • 28

    May

  • 05

    Jun

AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Recommendations
Amazon.com analyst commentary  »

Amazon online retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Earnings
Novartis confirms FY18 revenue guidance of growth of low to mid single-digit »

Novartis noted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Hot Stocks
Novartis reports Q1 Alcon sales of $1.8B »

Alcon net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

RDN

Radian Group

$15.36

-0.91 (-5.59%)

05:30
04/19/18
04/19
05:30
04/19/18
05:30
Recommendations
Radian Group analyst commentary  »

Radian Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Hot Stocks
Novartis Q1 results continue to demonstrate benefit from turnaround plan actions »

Novartis noted, Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Downgrade
MGIC Investment rating change  »

MGIC Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

, MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:28
04/19/18
04/19
05:28
04/19/18
05:28
Downgrade
Essent Group, MGIC Investment, Radian Group rating change  »

Essent Group downgraded…

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

RDN

Radian Group

$15.36

-0.91 (-5.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 04

    May

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:27
04/19/18
04/19
05:27
04/19/18
05:27
Hot Stocks
Novartis reports Q1 Sandoz net sales of $2.5B »

Sandoz net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:25
04/19/18
04/19
05:25
04/19/18
05:25
Earnings
Novartis reports Q1 core EPS $1.28, consensus $1.29 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

, TEVA

Teva

$17.91

0.065 (0.36%)

05:23
04/19/18
04/19
05:23
04/19/18
05:23
Hot Stocks
Procter & Gamble acquires Consumer Health business of Merck KGaA for EUR 3.4B »

Procter & Gamble (PG)…

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

TEVA

Teva

$17.91

0.065 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

  • 18

    May

  • 05

    Jun

  • 16

    Jun

GOL

GOL Linhas

$13.51

0.72 (5.63%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Downgrade
GOL Linhas rating change  »

GOL Linhas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Hot Stocks
Breaking Hot Stocks news story on Procter & Gamble »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

LN

Line Corp.

$38.30

0.09 (0.24%)

05:20
04/19/18
04/19
05:20
04/19/18
05:20
Downgrade
Line Corp. rating change  »

Line Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$177.84

-0.41 (-0.23%)

05:16
04/19/18
04/19
05:16
04/19/18
05:16
Recommendations
Apple analyst commentary  »

Mizuho sees risk to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

SNBR

Sleep Number

$36.58

-0.35 (-0.95%)

05:13
04/19/18
04/19
05:13
04/19/18
05:13
Downgrade
Sleep Number rating change  »

Sleep Number downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOV

National Oilwell

$38.32

0.73 (1.94%)

05:12
04/19/18
04/19
05:12
04/19/18
05:12
Downgrade
National Oilwell rating change  »

National Oilwell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 22

    May

PTEN

Patterson-UTI

$20.61

0.41 (2.03%)

05:12
04/19/18
04/19
05:12
04/19/18
05:12
Downgrade
Patterson-UTI rating change  »

Patterson-UTI downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 22

    May

ACET

Aceto

$7.40

0.04 (0.54%)

05:12
04/19/18
04/19
05:12
04/19/18
05:12
Downgrade
Aceto rating change  »

Aceto downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$48.58

-0.275 (-0.56%)

05:11
04/19/18
04/19
05:11
04/19/18
05:11
Upgrade
HSBC rating change  »

HSBC upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$32.08

0.54 (1.71%)

05:10
04/19/18
04/19
05:10
04/19/18
05:10
Upgrade
Liberty Global rating change  »

Liberty Global upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

DIOD

Diodes

05:10
04/19/18
04/19
05:10
04/19/18
05:10
Upgrade
Diodes rating change  »

Diodes upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 22

    May

TCBI

Texas Capital

$89.85

-0.25 (-0.28%)

05:10
04/19/18
04/19
05:10
04/19/18
05:10
Upgrade
Texas Capital rating change  »

Texas Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.